Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.

TitleThrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer.
Publication TypeJournal Article
Year of Publication2025
AuthorsWeng C-H, Assouvie A, Dong L, Beltra J-C, Budhu S, Mangarin L, Marouf Y, Morgado-Palacin L, Liu C, Monette S, Khan JF, Schulze I, Zamarin D, Hamadene L, Samaan F, Hirschhorn D, Pourpe S, Schröder D, Zappasodi R, Holland PM, Anandasabapathy N, E Wherry J, Wolchok JD, Merghoub T
JournalNat Immunol
Volume26
Issue12
Pagination2296-2311
Date Published2025 Dec
ISSN1529-2916
KeywordsAnimals, CD47 Antigen, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Humans, Immunotherapy, Lymphocytes, Tumor-Infiltrating, Mice, Mice, Inbred C57BL, Neoplasms, NFATC Transcription Factors, Signal Transduction, T-Cell Exhaustion, Thrombospondin 1
Abstract

T cell exhaustion is a major barrier to effective cancer immunotherapy. Although immune checkpoint blockade can reinvigorate exhausted T cells, not all patients achieve long-term responses, partly due to the refractory nature of terminally exhausted T cells. Beyond persistent antigen stimulation, the environmental drivers of exhaustion remain to be thoroughly characterized. Here we identify CD47 upregulation in tumor-infiltrating exhausted CD8+ T cells in both human and murine tumors. We reveal a novel role for the extracellular matrix protein thrombospondin-1 (TSP-1) in engaging CD47 on T cells to promote exhaustion. This interaction activates calcineurin-NFAT signaling, inducing upregulation of TOX and expression of inhibitory receptors, and impairing effector function during tumor progression. Importantly, disrupting the TSP-1-CD47 axis prevents T cell exhaustion and enhances tumor control. Our findings identify a novel pathway promoting T cell dysfunction and suggest that targeting the TSP-1-CD47 axis is a promising strategy to enhance T cell immunity and immunotherapy efficacy.

DOI10.1038/s41590-025-02321-5
Alternate JournalNat Immunol
PubMed ID41249483
PubMed Central ID4889009
Grant ListR01 CA249294 / CA / NCI NIH HHS / United States
P30CA008748 / / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) /
BCRF-22-176; BCRF-23-176 / / Breast Cancer Research Foundation (BCRF) /
W81XWH-21-1-0101 / / U.S. Department of Defense (United States Department of Defense) /
N/A / / Ludwig Institute for Cancer Research (Ludwig Cancer Research) /
W81XWH-20-1-0723 / / U.S. Department of Defense (United States Department of Defense) /
R01 AR080436 / AR / NIAMS NIH HHS / United States
R01 AR083208 / AR / NIAMS NIH HHS / United States